Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats

Cannabidiol (CBD) is known for its vasorelaxant (including in the human pulmonary artery), anti-proliferative and anti-inflammatory properties. The aim of our study was to examine the potential preventive effect of chronic CBD administration (10 mg/kg/day for three weeks) on monocrotaline (MCT)-indu...

Full description

Bibliographic Details
Main Authors: Olga Sadowska, Marta Baranowska-Kuczko, Anna Gromotowicz-Popławska, Michał Biernacki, Aleksandra Kicman, Barbara Malinowska, Irena Kasacka, Anna Krzyżewska, Hanna Kozłowska
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/19/7077
id doaj-98bfab60980e474788098b8dcbcceaee
record_format Article
spelling doaj-98bfab60980e474788098b8dcbcceaee2020-11-25T03:53:45ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-09-01217077707710.3390/ijms21197077Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in RatsOlga Sadowska0Marta Baranowska-Kuczko1Anna Gromotowicz-Popławska2Michał Biernacki3Aleksandra Kicman4Barbara Malinowska5Irena Kasacka6Anna Krzyżewska7Hanna Kozłowska8Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, PolandDepartment of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, PolandDepartment of Biopharmacy, Medical University of Białystok, 15-222 Białystok, PolandDepartment of Analytical Chemistry, Medical University of Białystok, 15-222 Białystok, PolandDepartment of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, PolandDepartment of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, PolandDepartment of Histology and Cytophysiology, Medical University of Bialystok, 15-222 Bialystok, PolandDepartment of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, PolandDepartment of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, PolandCannabidiol (CBD) is known for its vasorelaxant (including in the human pulmonary artery), anti-proliferative and anti-inflammatory properties. The aim of our study was to examine the potential preventive effect of chronic CBD administration (10 mg/kg/day for three weeks) on monocrotaline (MCT)-induced pulmonary hypertension (PH) rats. PH was connected with elevation of right ventricular systolic pressure; right ventricle hypertrophy; lung edema; pulmonary artery remodeling; enhancement of the vasoconstrictor and decreasing vasodilatory responses; increases in plasma concentrations of tissue plasminogen activator, plasminogen activator inhibitor type 1 and leukocyte count; and a decrease in blood oxygen saturation. CBD improved all abovementioned changes induced by PH except right ventricle hypertrophy and lung edema. In addition, CBD increased lung levels of some endocannabinoids (anandamide, <i>N</i>-arachidonoyl glycine, linolenoyl ethanolamide, palmitoleoyl ethanolamide and eicosapentaenoyl ethanolamide but not 2-arachidonoylglycerol). CBD did not affect the cardiopulmonary system of control rats or other parameters of blood morphology in PH. Our data suggest that CBD ameliorates MCT-induced PH in rats by improving endothelial efficiency and function, normalization of hemostatic alterations and reduction of enhanced leukocyte count determined in PH. In conclusion, CBD may be a safe, promising therapeutic or adjuvant therapy agent for the treatment of human pulmonary artery hypertension.https://www.mdpi.com/1422-0067/21/19/7077cannabidiolpulmonary hypertensionisolated vesselsPAI-1t-PAendocannabinoids
collection DOAJ
language English
format Article
sources DOAJ
author Olga Sadowska
Marta Baranowska-Kuczko
Anna Gromotowicz-Popławska
Michał Biernacki
Aleksandra Kicman
Barbara Malinowska
Irena Kasacka
Anna Krzyżewska
Hanna Kozłowska
spellingShingle Olga Sadowska
Marta Baranowska-Kuczko
Anna Gromotowicz-Popławska
Michał Biernacki
Aleksandra Kicman
Barbara Malinowska
Irena Kasacka
Anna Krzyżewska
Hanna Kozłowska
Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats
International Journal of Molecular Sciences
cannabidiol
pulmonary hypertension
isolated vessels
PAI-1
t-PA
endocannabinoids
author_facet Olga Sadowska
Marta Baranowska-Kuczko
Anna Gromotowicz-Popławska
Michał Biernacki
Aleksandra Kicman
Barbara Malinowska
Irena Kasacka
Anna Krzyżewska
Hanna Kozłowska
author_sort Olga Sadowska
title Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats
title_short Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats
title_full Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats
title_fullStr Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats
title_full_unstemmed Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats
title_sort cannabidiol ameliorates monocrotaline-induced pulmonary hypertension in rats
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-09-01
description Cannabidiol (CBD) is known for its vasorelaxant (including in the human pulmonary artery), anti-proliferative and anti-inflammatory properties. The aim of our study was to examine the potential preventive effect of chronic CBD administration (10 mg/kg/day for three weeks) on monocrotaline (MCT)-induced pulmonary hypertension (PH) rats. PH was connected with elevation of right ventricular systolic pressure; right ventricle hypertrophy; lung edema; pulmonary artery remodeling; enhancement of the vasoconstrictor and decreasing vasodilatory responses; increases in plasma concentrations of tissue plasminogen activator, plasminogen activator inhibitor type 1 and leukocyte count; and a decrease in blood oxygen saturation. CBD improved all abovementioned changes induced by PH except right ventricle hypertrophy and lung edema. In addition, CBD increased lung levels of some endocannabinoids (anandamide, <i>N</i>-arachidonoyl glycine, linolenoyl ethanolamide, palmitoleoyl ethanolamide and eicosapentaenoyl ethanolamide but not 2-arachidonoylglycerol). CBD did not affect the cardiopulmonary system of control rats or other parameters of blood morphology in PH. Our data suggest that CBD ameliorates MCT-induced PH in rats by improving endothelial efficiency and function, normalization of hemostatic alterations and reduction of enhanced leukocyte count determined in PH. In conclusion, CBD may be a safe, promising therapeutic or adjuvant therapy agent for the treatment of human pulmonary artery hypertension.
topic cannabidiol
pulmonary hypertension
isolated vessels
PAI-1
t-PA
endocannabinoids
url https://www.mdpi.com/1422-0067/21/19/7077
work_keys_str_mv AT olgasadowska cannabidiolamelioratesmonocrotalineinducedpulmonaryhypertensioninrats
AT martabaranowskakuczko cannabidiolamelioratesmonocrotalineinducedpulmonaryhypertensioninrats
AT annagromotowiczpopławska cannabidiolamelioratesmonocrotalineinducedpulmonaryhypertensioninrats
AT michałbiernacki cannabidiolamelioratesmonocrotalineinducedpulmonaryhypertensioninrats
AT aleksandrakicman cannabidiolamelioratesmonocrotalineinducedpulmonaryhypertensioninrats
AT barbaramalinowska cannabidiolamelioratesmonocrotalineinducedpulmonaryhypertensioninrats
AT irenakasacka cannabidiolamelioratesmonocrotalineinducedpulmonaryhypertensioninrats
AT annakrzyzewska cannabidiolamelioratesmonocrotalineinducedpulmonaryhypertensioninrats
AT hannakozłowska cannabidiolamelioratesmonocrotalineinducedpulmonaryhypertensioninrats
_version_ 1724476824055971840